BOSTON, April 7, 2014 /PRNewswire/ -- PAREXEL
International (NASDAQ: PRXL), a leading global biopharmaceutical
services organization, today announced Dr. Roland Andersson, Ph.D., and Dr. Thomas Senderovitz, M.D., as Senior Vice
Presidents in the Company's Clinical Research Services (CRS)
strategic business unit. The executives will be centrally involved
in developing and implementing PAREXEL's global corporate
objectives.
"Roland Andersson and
Thomas Senderovitz further
strengthen our CRS senior leadership team with a breadth of
biopharmaceutical experience, industry knowledge, and proven
strategic guidance," said Mark A.
Goldberg, M.D., President and Chief Operating Officer,
PAREXEL. "Under their collective leadership, we are well positioned
to expand our global CRS infrastructure and innovate in ways that
help simplify clients' drug development journeys."
Dr. Andersson will have overall responsibility for the
management of PAREXEL's Phase II-III client relationships on a
global basis, including strategic accounts and the Company's
Biopharm Unit that focuses on the needs of small and emerging
companies. He has extensive experience leading and transforming
businesses within the biotechnology, pharmaceutical and medical
device sectors. His primary expertise is in research and
development management, transformation, strategy, and business
development. Prior to joining PAREXEL, Dr. Andersson served as
managing director at Accenture, where he oversaw technology,
consulting and business services for leading pharmaceutical and
biotech companies. While at Accenture, he played a pivotal role in
creating TransCelerate BioPharma, an industry group that aligns the
world's best-known biopharmaceutical companies to address common
drug development problems. Dr. Andersson received an MS in
Engineering and a Ph.D. in Management from Linkoping Institute of
Technology, Sweden.
Dr. Senderovitz will have global management responsibility for
PAREXEL's Early Phase and Clinical Logistics business units, as
well as the Global Medical Services function. He joins the Company
from Grunenthal, an international research-based pharmaceutical
company headquartered in Germany,
where he served as executive vice president of Global Compound
Development. At Grunenthal, Dr. Senderovitz provided strategic
development and project oversight for all clinical development
functions, including Early Clinical Development, Late Stage
Clinical Development, Global Clinical Operations, and Global
Biometrics. Before joining Grunenthal, Dr. Senderovitz was
Vice President of Global Exploratory Development at UCB and Vice
President of Clinical R&D at Ferring Pharmaceuticals. He
received his M.D. from the Faculty of Medicine at the University of Copenhagen.
About PAREXEL International
PAREXEL International Corporation is a leading global
biopharmaceutical services organization, providing a broad range of
knowledge-based contract research, consulting, medical
communications, and technology solutions and services to the
worldwide pharmaceutical, biotechnology and medical device
industries. Committed to providing solutions that expedite
time-to-market and peak-market penetration, PAREXEL has developed
significant expertise across the development and commercialization
continuum, from drug development and regulatory consulting to
clinical pharmacology, clinical trials management, medical
education and reimbursement. PAREXEL Informatics, Inc., a
subsidiary of PAREXEL, provides advanced technology solutions,
including medical imaging, to facilitate the clinical development
process. Headquartered near Boston,
Massachusetts, PAREXEL operates in 76 locations in 50
countries around the world, and has 15,100 employees. For
more information about PAREXEL International visit
www.PAREXEL.com.
PAREXEL and "Your Journey. Our Mission." are trademarks or
registered trademarks of PAREXEL International Corporation or its
affiliates.
This release contains "forward-looking" statements regarding
future results and events, including, without limitation,
statements regarding expected financial results, future growth and
customer demand. For this purpose, any statements
contained herein that are not statements of historical fact may be
deemed forward-looking statements. Without limiting the
foregoing, the words "believes," "anticipates," "plans," "expects,"
"intends," "appears," "estimates," "projects," "will," "would,"
"could," "should," "targets," and similar expressions are also
intended to identify forward-looking statements. The
forward-looking statements in this release involve a number of
risks and uncertainties. The Company's actual future results
may differ significantly from the results discussed in the
forward-looking statements contained in this release.
Important factors that might cause such a difference include, but
are not limited to, risks associated with: actual operating
performance; actual expense savings and other operating
improvements resulting from recent and anticipated restructurings;
the loss, modification, or delay of contracts which would, among
other things, adversely impact the Company's recognition of revenue
included in backlog; the Company's dependence on certain industries
and clients; the Company's ability to win new business, manage
growth and costs, and attract and retain employees; the Company's
ability to complete additional acquisitions, and to integrate newly
acquired businesses including the recent acquisitions of LIQUENT,
Inc. and HERON, Inc., or enter into new lines of business; the
impact on the Company's business of government regulation of the
drug, medical device and biotechnology industry; consolidation
within the pharmaceutical industry and competition within the
biopharmaceutical services industry; the potential for significant
liability to clients and third parties; the potential adverse
impact of health care reform; and the effects of exchange rate
fluctuations and other international economic, political, and other
risks. Such factors and others are discussed more fully
in the section entitled "Risk Factors" of the Company's Quarterly
Report on Form 10-Q for the fiscal quarter ended December 31, 2013 as filed with the SEC on
January 31, 2014, which "Risk
Factors" discussion is incorporated by reference in this press
release. The Company specifically disclaims any obligation to
update these forward-looking statements in the future. These
forward-looking statements should not be relied upon as
representing the Company's estimates or views as of any date
subsequent to the date of this press release.
Contacts:
Diana Martin,
Vice President, Corporate Communications
PAREXEL International
Tel: +1 781-434-5516
Email: Diana.Martin@PAREXEL.com
Matthew Briggs
PAN Communications
Tel: +1 617-502-4300
Email: PAREXEL@pancomm.com
SOURCE PAREXEL International